NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification

NeuroBo Pharmaceuticals, Inc. (NRBO) announced Data Monitoring Committee's recommendation to continue enrollment of the phase 2/3 clinical trial, without modification, for lead drug candidate, ANA001, as a potential treatment for COVID-19. The company plans to complete the phase 2 portion of the trial in the fourth quarter of the current year and to achieve a number of value-creating milestones with this program in the coming months, including initiation of the phase 3 of trial.

The phase 2 part of the trial is anticipated to enroll 60 patients and the primary objective is to assess safety and tolerability. The phase 3 is expected to enroll several hundred patients, with the primary endpoints being median time to hospital discharge, safety and tolerability.

Shares of NeuroBo Pharmaceuticals were up 19% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines said it sees weather-related flight cancelations as AT&T and Verizon readies for 5G roll out in and around the vicinity of major U.S. airports. Most of the other airlines also confirmed the same as the implementation of the new C-Band 5G service is expected to interfere with the working of onboard aircraft instruments. Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues...
Follow RTT